Skip to main content
ERC
Publications
Participate
Patients
Doctors
Investors
Products
Gliovac/ERC1671
Media
News
Publications
About
Executive Management
Executive board
Scientific board
Milestone achievements
Contact
News
Publications
Dec
2022
ERC Belgium balance sheet for the financial year ending 31 Dec 2022
Jul
2022
Cohort Study of GLIOVAC/ERC1671/SITOIGANAP to treat Glioblastoma
Aug
2018
Review - Therapeutic Immunization against Glioblastoma – Virgil Schijns
Aug
2018
Phase II study of ERC1671/SITOIGANAP plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.
Jan
2018
Therapeutic vaccination against malignant gliomas Q1 based on allorecognition and syngeneic tumor antigens: Proof of principle in two strains of rat
Oct
2015
Use of ERC-1671/SITOIGANAP Vaccine in a patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.
May
2015
Therapeutic vaccination against malignant gliomas Q1 based on allorecognition and syngeneic tumor antigens: Proof of principle in two strains of rat.
Apr
2015
First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined all- and auto-immune tumor reactivity.
Jul
2012
Cancer Immunology.
May
2012
Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation
Pages
1
2
next ›
last »
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our
Cookie and Privacy Policy
for more details.
Close